Feasibility and acceptability of the patient-reported outcomes measurement information system measures in children and adolescents in active cancer treatment and survivorship.
Feasibility and acceptability of the patient-reported outcomes measurement information system measures in children and adolescents in active cancer treatment and survivorship.
复制标题
DOI：
10.1097/ncc.0b013e3182a0e23d
复制
发表时间：
2014-01
期刊：
影响因子：
2.6
通讯作者：
Gross HE
中科院分区：
文献类型：
--
作者：
Menard JC;Hinds PS;Jacobs SS;Cranston K;Wang J;DeWalt DA;Gross HE
癌症治疗期间和之后与症状、功能和生活质量相关的患者报告结局（PRO）可以指导儿科癌症患者的护理。为了推进PRO科学，美国国立卫生研究院资助了患者报告结局测量信息系统（PROMIS）。评估PROMIS儿科指标的可行性和可接受性，定义为入组率和脱落率以及指标、项目、受试者和评估时间点的缺失率。8至18奥尔兹参与了两项研究：PROMIS I，一项针对积极接受癌症治疗或存活儿童的横断面研究，以及PROMIS II，一项针对接受治愈性治疗儿童的3个评估时间点的纵向研究。PROMIS I（n=200）和PROMIS II（n=94）的入组率分别为92.5%和89.7%。对于PROMIS I，测量缺失是可接受的（8%缺失任何测量），与其他研究变量无关。对于PROMIS II，测量缺失最小（0.8%），项目级缺失相对较低。一般来说，跳过的项目询问参与者在过去7天内没有遇到的经历。在这两项研究中，PROMIS仪器在儿科癌症患者中表现出良好的可行性和可接受性。总体而言，我们有高入组率，低损耗率，以及可接受的测量和项目缺失率。我们的研究结果表明，PROMIS措施是可以接受的，8至18岁的儿童在不同的癌症护理点和可行的用于儿科癌症住院和门诊设置。
Patient-reported outcomes (PROs) related to symptoms, function, and quality of life during and following cancer treatment can guide care for pediatric cancer patients. To advance the science of PROs, the National Institutes of Health funded the Patient Reported Outcomes Measurement Information System (PROMIS). To assess feasibility and acceptability of the PROMIS pediatric measures, as defined by enrollment and attrition rates as well as missingness by measure, item, participant, and assessment time point. 8-to-18 year olds participated in two studies: PROMIS I, a cross-sectional study of children in active cancer treatment or survivorship, and PROMIS II, a longitudinal study with 3 assessment time points for children receiving curative treatment. PROMIS I (n=200) and PROMIS II (n=94) had enrollment rates of 92.5% and 89.7%, respectively. For PROMIS I, measure missingness was acceptable (8% missed any measures) and was not related to other study variables. For PROMIS II, measure missingness was minimal (0.8%), and item-level missingness was relatively low. In general, items that were skipped asked about experiences that participants had not encountered in the past 7 days. In both studies, the PROMIS instruments demonstrated good feasibility and acceptability among pediatric cancer patients. Overall, we had high enrollment, low attrition, and acceptable rates of measure and item missingness. Our results demonstrate that PROMIS measures are acceptable to 8-to-18 year-olds in different points of cancer care and feasible for use in pediatric cancer inpatient and outpatient settings.